Development and evaluation of choline tagged mesoporous silica nanoparticles for targeted delivery and imaging in prostate cancer.
2/5 보강
OpenAlex 토픽 ·
Nanoparticle-Based Drug Delivery
Mesoporous Materials and Catalysis
Nanoplatforms for cancer theranostics
This study presents MSNCHDT@DTX, mesoporous silica nanoparticles (MSN) functionalized with choline and diethylenetriaminepentaacetic acid (DTPA), designed as a theranostic agent integrating targeting,
APA
Nikhil Kumar, Pritha Bose, et al. (2026). Development and evaluation of choline tagged mesoporous silica nanoparticles for targeted delivery and imaging in prostate cancer.. Nanomedicine : nanotechnology, biology, and medicine, 102948. https://doi.org/10.1016/j.nano.2026.102948
MLA
Nikhil Kumar, et al.. "Development and evaluation of choline tagged mesoporous silica nanoparticles for targeted delivery and imaging in prostate cancer.." Nanomedicine : nanotechnology, biology, and medicine, 2026, pp. 102948.
PMID
42031040 ↗
Abstract 한글 요약
This study presents MSNCHDT@DTX, mesoporous silica nanoparticles (MSN) functionalized with choline and diethylenetriaminepentaacetic acid (DTPA), designed as a theranostic agent integrating targeting, imaging, and therapy. Docetaxel (DTX) use in prostate cancer is limited by poor water solubility and systemic toxicity. Exploiting elevated choline uptake in PC-3 cells, MSN were covalently functionalized with choline and DTPA, with DTX subsequently encapsulated within the mesoporous framework. Structure elucidating techniques confirmed successful synthesis, while comprehensive physicochemical characterization validated the grafting of choline and DTPA onto the nanoparticle surface and confirmed drug encapsulation. The system demonstrated stability under physiological conditions and high selectivity for PC-3 human prostate cancer cells, achieving ~88% increased cellular uptake. Cytotoxic activity surpassed both non-targeted nanoparticles and free drug, with an IC of 20 μg/mL at 48 h. By selectively targeting cancerous cells while sparing healthy tissue, MSNCHDT@DTX represents a promising advancement in prostate cancer theranostics.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- A true theranostic pair - Sc-labeled GRPR antagonist shows great promise for managing prostate and breast cancer.
- Precision Assay for Detection and Quantification of Anti-Prostate Specific Antigen Antibodies Using Indirect ELISA.
- Preclinical Evaluation of a Lu-Labeled Gastrin-Releasing Peptide Receptor Antagonist and Prostate Cancer Treatment with Monotherapy and in Combination with Everolimus.
- Association of Proteinuria With Disease Stage and Treatment Response in Patients With Lymphoma: A Prospective Cohort Study.
- Reconstruction of Clival Defects using Vascularized Free and Pedicled Flaps: Systematic Review and Proposed Algorithms.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Real-world Treatment Selection and Shared Decision-making in De Novo Metastatic Castration-sensitive Prostate Cancer in Japan.
- Vibostolimab Coformulated with Pembrolizumab in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: KEYNOTE-365 Cohort G.
- Characterization and validation of a bone metastatic castration-resistant prostate cancer model as a nanomedicine evaluation platform.
- Harnessing Folate-Mediated PSMA Targeting for Precision Therapy: An Intelligent Liposomal Nanoplatform Against Prostate Cancer.
- Menopausal Status Associated With Docetaxel-Induced Vascular Dysfunction in Breast Cancer Patients.
- Results from a Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer with DNA Homologous Recombination Repair Deficiency.